{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:02:58Z","timestamp":1773284578523,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,2,28]],"date-time":"2011-02-28T00:00:00Z","timestamp":1298851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:p>S. Radunz, B. Juntermanns, G.M. Kaiser, J. Treckmann, Z. Mathe, A. Paul, F.H. Saner. Efficacy and safety of linezolid in liver transplant patients\u2028Transpl Infect Dis 2011: <jats:bold>13:<\/jats:bold> 353\u2013358. All rights reserved<\/jats:p><jats:p><jats:bold>Abstract: <\/jats:bold> Bacterial infections are the main cause of death within the first year after liver transplantation, and the increased incidence of multidrug\u2010resistant gram\u2010positive pathogens has created a major challenge in the treatment of these patients. Linezolid, the first US Food &amp; Drug Administration\u2010approved oxazolidinone, offers a valuable novel treatment option for serious gram\u2010positive infections. Linezolid is relatively non\u2010toxic but prolonged treatment with linezolid was associated with thrombocytopenia. Here we report on the experience of linezolid treatment in adult liver transplant patients, who are at an increased risk for thrombocytopenia because of hypersplenism. From November 2003 until December 2009, we evaluated the clinical course of 46 liver transplant patients (27 male\/19 female) in our surgical intensive care unit. For proven or probable gram\u2010positive infection, all patients received linezolid 600\u2003mg intravenously every 12\u2003h. On clinical improvement, treatment was changed to oral linezolid 600\u2003mg twice daily. Treatment duration was 11 \u00b1 7 days. Treatment indications were pneumonia (<jats:italic>n<\/jats:italic>=8), blood stream infection (<jats:italic>n<\/jats:italic>=30), and surgical site\/abdominal infection (<jats:italic>n<\/jats:italic>=3). Clinical cure was achieved in 43 out of 46 patients. During the course of treatment, no cases of severe thrombocytopenia occurred and a statistically significant platelet count increase was seen from day 1 (110 \u00b1 73\/nL) to day 7 (165 \u00b1 116\/nL) and day 14 (180 \u00b1 140\/nL). We did not observe any further adverse events, especially no severe neurological complications (e.g., serotonin syndrome) or signs of lactate acidosis. Two patients died from uncontrolled vancomycin\u2010resistant <jats:italic>Enterococcus faecium<\/jats:italic> sepsis with septic shock and one due to uncontrolled methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> pneumonia. These deaths were considered to be unrelated to linezolid treatment, and linezolid was regarded as the optimal treatment choice in these patients. A subgroup analysis of patients treated for &gt;14 days revealed no statistically significant differences when compared with patients on shorter treatment. In particular, no cases of thrombocytopenia occurred during longer treatment. In conclusion, linezolid is a safe and effective treatment for adult liver transplant patients with gram\u2010positive infections.<\/jats:p>","DOI":"10.1111\/j.1399-3062.2011.00617.x","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T20:41:44Z","timestamp":1299012104000},"page":"353-358","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of linezolid in liver transplant patients"],"prefix":"10.1111","volume":"13","author":[{"given":"S.","family":"Radunz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Juntermanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Treckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Mathe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.H.","family":"Saner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31816f61a6"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199905000-00020"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-3-200108070-00009"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/382690"},{"issue":"8","key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajic.2004.10.001","article-title":"System Report, data summary from January 1992 through June 2004, issued October 2004","volume":"32","author":"National Nosocomial Infections Surveillance (NNIS).","year":"2004","journal-title":"Am J Infect Control"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9509556"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/340353"},{"issue":"3","key":"e_1_2_5_9_2","first-page":"311","article-title":"Linezolid treatment for gram\u2010positive infections","volume":"21","author":"Tascini C","year":"2009","journal-title":"a retrospective comparison with teicoplanin"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh088"},{"issue":"3","key":"e_1_2_5_11_2","first-page":"402","article-title":"Linezolid (PNU\u2010100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia","volume":"32","author":"Rubinstein E","year":"2001","journal-title":"a randomized, double-blind, multicenter study"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80118-2"},{"issue":"5","key":"e_1_2_5_13_2","first-page":"1789","article-title":"Linezolid vs vancomycin","volume":"124","author":"Wunderink RG","year":"2003","journal-title":"analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia"},{"issue":"2","key":"e_1_2_5_14_2","first-page":"345","article-title":"Linezolid versus teicoplanin in the treatment of gram\u2010positive infections in the critically ill","volume":"53","author":"Cepeda JA","year":"2004","journal-title":"a randomized, double-blind, multicentre study"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/500139"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/338403"},{"issue":"3","key":"e_1_2_5_17_2","first-page":"121","article-title":"Linezolid in the treatment of vancomycin\u2010resistant Enterococcus faecium in solid organ transplant recipients","volume":"5","author":"El\u2010Khoury J","year":"2003","journal-title":"report of a multicenter compassionate-use trial"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0011"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm369"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000217961.75225.E9"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.118.1.146"},{"issue":"10","key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200003093421007","article-title":"Vancomycin\u2010resistant enterococcal infections","volume":"342","author":"Murray BE.","year":"2000","journal-title":"N Engl J Med"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199802150-00027"},{"issue":"2","key":"e_1_2_5_24_2","first-page":"322","article-title":"Methicillin\u2010resistant Staphylococcus aureus","volume":"30","author":"Singh N","year":"2000","journal-title":"the other emerging resistant gram-positive coccus among liver transplant recipients"},{"issue":"4","key":"e_1_2_5_25_2","first-page":"346","article-title":"Management of Staphylococcus aureus bacteremia and endocarditis","volume":"23","author":"Kern WV.","year":"2010","journal-title":"progresses and challenges"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-3062.2011.00617.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-3062.2011.00617.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T14:27:02Z","timestamp":1698762422000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-3062.2011.00617.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,28]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1399-3062.2011.00617.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-3062.2011.00617.x","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,28]]}}}